Jonathan M. Budzik

Learn More
BACKGROUND Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteristics of PZA resistant tuberculosis. METHODS Using a retrospective cohort study design, we evaluated(More)
  • 1